ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 114,49
0,72%
DAX
18 254,18
1,03%
Brent Oil
85,11
0,49%
Bitcoin
64 913,72
-0,08%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Edgewise Therapeutics Inc (EWTX)

  7. Edgewise Therapeutics Inc (EWTX) Actualités

EWTX Edgewise Therapeutics Inc

16,80
0,62 (3,83%)
Dernière mise à jour : 21:22:14
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Edgewise Therapeutics Inc EWTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,62 3,83% 16,80 21:22:14
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
16,04 16,04 17,14 16,18
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
13/6/202401:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202415:10EDGAR2Form 8-K - Current report
10/5/202415:07EDGAR2Form S-3ASR - Automatic shelf registration statement of..
10/5/202414:00BWEdgewise Therapeutics to Present at the RBC Capital Markets..
09/5/202415:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/5/202414:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202414:00EDGAR2Form 8-K - Current report
09/5/202414:00BWEdgewise Therapeutics Reports First Quarter 2024 Financial..
07/5/202415:16EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/5/202415:14EDGAR2Form 8-K - Current report
07/5/202414:00BWEdgewise Therapeutics Appoints Arlene Morris to its Board of..
06/5/202414:00BWEdgewise Therapeutics Doses First Patient in Phase 2..
23/4/202414:00BWEdgewise Receives European Medicines Agency (EMA) Orphan..
15/4/202422:05BWEdgewise Therapeutics Announces Positive Two-Year Topline..
28/3/202413:00BWEdgewise Therapeutics Announces Upcoming Podium Presentation..
27/3/202413:00BWEdgewise Therapeutics to Present at the Cantor Virtual..
05/3/202414:00BWEdgewise Therapeutics to Present at the Leerink Partners..
28/2/202414:00BWEdgewise Therapeutics to Present on EDG-5506 for the..
22/2/202414:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202414:00EDGAR2Form 8-K - Current report
22/2/202414:00BWEdgewise Therapeutics Reports Fourth Quarter and Full Year..
14/2/202414:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202414:00BWEdgewise Receives U.S. FDA Fast Track Designation for..
09/2/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:15EDGAR2Form 144 - Report of proposed sale of securities
19/1/202422:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202414:44EDGAR2Form 8-K - Current report
19/1/202414:37BWEdgewise Therapeutics Announces Pricing of $240 Million..
19/1/202412:05EDGAR2Form 8-K - Current report
19/1/202412:04EDGAR2Form S-3MEF - Registration adding securities to prior Form..
19/1/202412:02EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
09/1/202414:39BWEdgewise Therapeutics Highlights 2023 Accomplishments and..
28/12/202322:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202322:32EDGAR2Form 144 - Report of proposed sale of securities
19/12/202314:00BWEdgewise Therapeutics to Present at the 42nd Annual J.P...
18/12/202314:00BWEdgewise Therapeutics Launches First of Its Kind Educational..
30/11/202314:56DJNEdgewise Gets FDA Orphan, Rare-Pediatric-Disease..
30/11/202314:00BWEdgewise Receives Orphan Drug and Rare Pediatric Disease..
09/11/202314:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:00EDGAR2Form 8-K - Current report
09/11/202314:00BWEdgewise Therapeutics Reports Third Quarter 2023 Financial..
08/11/202314:00BWEdgewise Therapeutics to Present at Upcoming Investor..
01/11/202313:00BWEdgewise to Present Data on EDG-7500 at the American Heart..
26/10/202314:00BWEdgewise Therapeutics Announces Expansion of their EDG-5506..
27/9/202314:00BWEdgewise Therapeutics to Present on EDG-5506 for Becker..
26/9/202314:00BWEdgewise Therapeutics Announces Initiation of GRAND CANYON,..
14/9/202314:00BWEdgewise Therapeutics Begins Dosing First-in-Human Phase 1..
19/8/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/8/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202314:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
EWTX
Edgewise Therapeutics
NYSE
RNR
RenaissanceRe
ASX
XL8
XLR8 Metals
BIT
P1YPE1
NLBNPIT1YPE1 20240621 40
BIT
UV4MB0
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés